• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

DRAXIS appoints new president

Article

Richard Flanagan has been named president of DRAXIS’ radiopharmaceutical subsidiary, DRAXIMAGE. He has succeeded Ray Dore, who plans to retire in September but will continue to serve as a special advisor. Flanagan, who is currently executive vice

Richard Flanagan has been named president of DRAXIS’ radiopharmaceutical subsidiary, DRAXIMAGE. He has succeeded Ray Dore, who plans to retire in September but will continue to serve as a special advisor. Flanagan, who is currently executive vice president, has been with DRAXIMAGE since its founding in 1997.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.